The effect sizes for the per-protocol population primary and secondary neurological endpoints, which did not reach statistical significance, were comparable to those obtained with approved AD medications and were consistent in direction of improvement.
← all excerpts
An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease.
1
—
—